Abstract:Objective: To study the antiangiogenic activity of recombinant eukaryotic expression vectors carrying genes encoding attenuated Shiga-like toxin Ⅰ (Stx1) mutant in vitro and in vivo. Methods: CHO cells were transfected with two eukaryotic expression plasmids harboring attenuated Stx1 mutant genes (pcDNA3.1-Stx1D10 and pcDNA3.1-Stx1D100) by liposome and FACS was used to study its influence on CHO cells. CHO cells stably expressing 1/10 and 1/100 attenuated Stx1 mutants were established. The culture supernatants of the above 2 cell lines and the control cells were used to treat human umbilical vein endothelial cells (HUVEC), and their influences on the proliferation, migration, and the tubule forming ability HUVEC were observed. Eukaryotic expression vectors carrying Stx1 mutants were locally injected into nude mice bearing human ovarian cancer cells SKOV3 to observe its antiangiogenic effect in tumors. Results: CHO cells showed no obvious apoptosis or necrosis after transfected by attenuated Stx1 mutants. The transcription and stable expression of Stx1 mutants were verified by RT-PCR and by Western blotting analysis in mutant Stx1 gene-integrated CHO cells. The supernatants of mutant Stx1 gene-integrated CHO cells had antiproliferative effect on HUVEC compared with control supernatant (P0.05), and this effect could be blocked by monoclonal antibody against Stx1 B-subunit; furthermore, these supernatants significantly decreased migration and capillary tube formation of HUVEC at a low dose. A significant decrease of microvessel density was observed in transplanted SKOV3 tumors in immunodeficient mice treated with pcDNA3.1-Stx1D10 or pcDNA3.1-Stx1D100 (P0.01). Conclusion: Two mutant Stx1 gene-integrated CHO cell lines which stably express attenuated mutants of Stx1 have been successfully established. The attenuated Stx1 mutants in this study can effectively inhibit the growth and function of HUVEC; they also have in vivo antiangiogenic activity on transplanted SKOV3 tumors in immunodeficient mice.

[Development of toxin targeting to VEGF-KDR].

Synthesis and Characterization of Chemical Conjugate Targeting KDR

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

A fusion protein targeting the vascular endothelial growth factor receptor I (VEGFR-1)

[Screening for inhibitor of vascular endothelial growth factor from random peptide library].

Cloning of cDNA Encoding Extra-Cellular Domain of Human VEGF Receptor KDR and Effect of Its Recombinant Protein on Endothelial Cell Proliferation and Angiogenesis

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

Preparation and characterization of RGD tumour-homing-peptide-modified plasminogen K5.

A VEGFR Targeting Peptide-Drug Conjugate (PDC) Suppresses Tumor Angiogenesis in a TACE Model for Hepatocellular Carcinoma Therapy

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.

Targeting Matrix Metalloproteinases And Endothelial Cells With A Fusion Peptide Against Tumor

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

Peptide-based Vector of VEGF Plasmid for Efficient Gene Delivery in Vitro and Vessel Formation in Vivo.

Expression and Function Identification of Extracellular Domain 3 of Human Vascular Endothelial Growth Factor Receptor KDR

Cloning and expression of truncated KDR binding to vascular endothelial growth factor

Phage‐derived Fully Human Antibody Scfv Fragment Directed Against Human Vascular Endothelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF

Targeted Delivery of Diphtheria Toxin into VEGFR1/VEGFR2 Overexpressing Cells Induces Anti-angiogenesis Activity

Preparation of extracellular domain 3 of human VEGF receptor-2 and the monitoring of its real-time binding to VEGF by biosensors.

Antiangiogenic Activity of Recombinant Eukaryotic Expression Vectors Carrying Genes Encoding Attenuated Shiga-like Toxin Ⅰ Mutant

A Novel Small Peptide As a Targeting Ligand for Receptor Tyrosine Kinase Tie2